MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. Show more
Location: 4275 Executive Square, La Jolla, CA, 92037, United States | Website: https://medicinova.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
62.29M
52 Wk Range
$1.12 - $2.55
Previous Close
$1.27
Open
$1.26
Volume
10,529
Day Range
$1.26 - $1.32
Enterprise Value
28.03M
Cash
36.57M
Avg Qtr Burn
-2.64M
Insider Ownership
2.98%
Institutional Own.
21.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MN-166 (ibudilast) Details Neurological disorder, Degenerative Cervical Myelopathy | Phase 2/3 Data readout | |
MN-166 (ibudilast) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Phase 2/3 Data readout | |
MN-166 (ibudilast) Details Neuropathy, Neurological disorder | Phase 2b Data readout | |
MN-166 (ibudilast) Details Alcohol dependence | Phase 2b Update | |
MN-001 (tipelukast) Details Liver disease, Non-alcoholic steatohepatitis | Phase 2 Interim update | |
MN-166 (ibudilast) Details Glioblastoma, Cancer | Phase 2 Update | |
MN-166 (ibudilast) Details COVID-19 | Phase 2 Update | |
MN-001 (tipelukast) Details Interstitial lung disease, Lung disease, Idiopathic pulmonary fibrosis | Phase 2 Update | |
MN-166 (ibudilast) Details Multiple sclerosis, Central nervous system illness | Phase 2 Update | |
SAR444836 Details Phenylketonuria | Phase 1/2 Data readout |